UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

The New England journal of medicine, 2016-06, Vol.374 (26), p.2530-2541

2016

Link zum Volltext

Verfügbarkeit prüfen

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

The New England journal of medicine, 2009-11, Vol.361 (22), p.2113-2122

2009

Link zum Volltext

Verfügbarkeit prüfen

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

Mayo Clinic proceedings, 2013-02, Vol.88 (2), p.139-148

2013

Link zum Volltext

Verfügbarkeit prüfen

Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

Pharmacotherapy, 2010-08, Vol.30 (8), p.787-796

2010

Link zum Volltext

Verfügbarkeit prüfen

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration

Journal of the American College of Cardiology, 2010-06, Vol.55 (24), p.2721-2726

2010

Link zum Volltext

Verfügbarkeit prüfen

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

Journal of personalized medicine, 2013-06, Vol.3 (2), p.111-123

2013

Link zum Volltext

Verfügbarkeit prüfen

Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe

European heart journal, 2012-12, Vol.33 (23), p.2939-2945

2012

Link zum Volltext

Verfügbarkeit prüfen

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Journal of the American College of Cardiology, 2010-06, Vol.55 (24), p.2721-2726

2010

Link zum Volltext

Verfügbarkeit prüfen

Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials

Pharmacotherapy, 2014-05, Vol.34 (5), p.452-463

2014

Link zum Volltext

Verfügbarkeit prüfen

On Pharmacogenomics in Pharmacy Benefit Management

Pharmacotherapy, 2012-02, Vol.32 (2), p.103-111

2012

Link zum Volltext

Verfügbarkeit prüfen

Flushing and the HDL-C response to extended-release niacin

Journal of clinical lipidology, 2008-08, Vol.2 (4), p.285-288

2008

Link zum Volltext

Verfügbarkeit prüfen

Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

Clinical therapeutics, 2007, Vol.29 (1), p.196-209

2007

Link zum Volltext

Verfügbarkeit prüfen

An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users

Journal of rheumatology, 2015-08, Vol.42 (8), p.1478

2015

Link zum Volltext

Verfügbarkeit prüfen

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting

Circulation (New York, N.Y.), 2005-02, Vol.111 (4), p.488-493

2005

Link zum Volltext

Verfügbarkeit prüfen

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study

European journal of clinical pharmacology, 2014-09, Vol.70 (9), p.1049-1057

2014

Link zum Volltext

Verfügbarkeit prüfen

Risk of cardiovascular events in patients at optimal values for combined lipid parameters

Current medical research and opinion, 2007-03, Vol.23 (3), p.553-563

2007

Link zum Volltext

Verfügbarkeit prüfen

Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events

Journal of clinical lipidology, 2008-10, Vol.2 (5), p.343-353

2008

Link zum Volltext

Verfügbarkeit prüfen

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

Journal of the American College of Cardiology, 2012-03, Vol.59 (13), p.E1848-E1848

2012

Link zum Volltext

Verfügbarkeit prüfen

Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients

The Annals of pharmacotherapy, 2004-07, Vol.38 (7-8), p.1136

2004

Link zum Volltext

Verfügbarkeit prüfen

Paradoxical progression of atherosclerosis related to low-density tipoprotein reduction and exposure to ezetimibe

European heart journal, 2012, Vol.33 (23), p.2939-2945

2012

Link zum Volltext

Verfügbarkeit prüfen

Amlodipine overdose

The Annals of pharmacotherapy, 1997-07, Vol.31 (7-8), p.853

1997

Link zum Volltext

Verfügbarkeit prüfen

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y^sub 12^ inhibition: Results of the randomized DOSAPI study

European journal of clinical pharmacology, 2014-09, Vol.70 (9), p.1049

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 16675: Assessment of Initial U.S. Dabigatran Utilization and Short-Term Persistence

Circulation (New York, N.Y.), 2011-11, Vol.124 (suppl_21)

2011

Link zum Volltext

Verfügbarkeit prüfen

Preferences for treatment outcomes in patients with heart failure: Symptoms versus survival

Journal of cardiac failure, 2000-09, Vol.6 (3), p.225-232

2000

Link zum Volltext

Verfügbarkeit prüfen

Abstract P241: One-Year Cost-Effectiveness of Cytochrome P450 2C19 Genotype-Guided Antiplatelet Therapy in Patients With Acute Coronary Syndromes

Circulation Cardiovascular quality and outcomes, 2011-11, Vol.4 (suppl_1)

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(72)
Berichte
(2)

Sprache

Englisch
(74)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials

On Pharmacogenomics in Pharmacy Benefit Management

Flushing and the HDL-C response to extended-release niacin

Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study

Risk of cardiovascular events in patients at optimal values for combined lipid parameters

Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients

Paradoxical progression of atherosclerosis related to low-density tipoprotein reduction and exposure to ezetimibe

Amlodipine overdose

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y^sub 12^ inhibition: Results of the randomized DOSAPI study

Abstract 16675: Assessment of Initial U.S. Dabigatran Utilization and Short-Term Persistence

Preferences for treatment outcomes in patients with heart failure: Symptoms versus survival

Abstract P241: One-Year Cost-Effectiveness of Cytochrome P450 2C19 Genotype-Guided Antiplatelet Therapy in Patients With Acute Coronary Syndromes

Suchergebnisse filtern